12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brilinta regulatory update

AstraZeneca said China's State Food and Drug Administration (SFDA) approved Brilinta ticagrelor prevent thrombotic cardiovascular events in patients with acute coronary syndromes (ACS). The pharma said the product will be immediately available for...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >